JAK2 and Thrombocytopenia: Therefore, it is very likely that the doses of JAK2 inhibitors employed, that are constrained by development of dose-dependent thrombocytopaenia and anaemia reflecting the essential role of JAK2 in normal haematopoiesis, are not sufficiently high to abrogate JAK2 signalling to such an extent to induce clonal cell death.